ECONOMIC IMPACT OVER THE PAST 4 YEARS ASSOCIATED WITH BIOLOGICAL THERAPY OPTIMISATION IN RHEUMATIC DISEASES PATIENTS

Cavada-Carranza I¹, Alonso-Zazo FJ¹, Martínez-Núñez ME³, Vázquez-Sánchez R¹, Sánchez-Rubio-Ferrández J¹, Aragón-Diez A², Rodríguez-Heredia JM², Molina-García T¹

¹Pharmacy Department Hospital Universitario de Getafe, ²Rheumatology Department Hospital Universitario de Getafe

OBJECTIVES

To evaluate biologic-therapies (BT) optimization patterns in patients with rheumatic diseases (RD) and associated economic savings

MATERIALS and METHODS

Observational and retrospective study
All patients with RD treated with BT from January 2014 to June 2018 were included

BT optimization
- Dose reduction
- Prolonging the dosing interval

Patients ≥ 6 months in CLINICAL REMISSION or MINIMAL CLINICAL ACTIVITY

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Subcutaneous BT</th>
<th>Dose regimens</th>
<th>Total treatment duration</th>
<th>Time on BT optimization (TO)</th>
<th>Treatment costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td>Adalimumab</td>
<td>60%</td>
<td>1.7</td>
<td>2,7</td>
<td>60%</td>
</tr>
<tr>
<td>SA</td>
<td>Adalimumab</td>
<td>53,7%</td>
<td>2,1</td>
<td>1,9</td>
<td>53,7%</td>
</tr>
<tr>
<td>PSA</td>
<td>Etanercept</td>
<td>33,1%</td>
<td>2,7</td>
<td>2,7</td>
<td>33,1%</td>
</tr>
</tbody>
</table>

Cost saving / patient ➔ Comparing optimization treatment costs vs conventional treatment
Cost saving globally ➔ Comparing real cost vs theoretical conventional doses cost

RESULTS

N= 448 → BT treatments= 579

Biologic-therapies optimization
- From all patients ➔ 47% was in BT optimization
- Adalimumab 60%
- The most common BT used in RD treatment

BT optimization/diagnosis

Time on BT optimization

Mean TO duration = 2,2 years

Cost saving

BT optimization allowed a 50% saving per patient against the use of conventional therapy

Reduction of the total cost

€3.000.000

Total economic savings

21%

CONCLUSIONS

✓ Therapeutic decision-making based on validated disease activity scales has allowed the BT optimization in approximately 50% of patients with RD
✓ Patients remain clinically controlled after BT optimization for a mean time of 2 years
✓ The BT optimization allows to reduce costs maintaining the effectiveness

ATC code: L04A
Immunosuppressant drugs